Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.67% is in line with its 3-year average of 0.62%, near the low end of its 3-year range (0.00%–30.02%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.93% below its 12-month average of 0.88%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.67%.
DEBT TO ASSETS RATIO
0.67%
DEBT TO ASSETS RATIO AVG TTM
0.88%
DEBT TO ASSETS RATIO AVG 3Y
0.62%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-23.93%
CURRENT VS 3Y AVG
+8.44%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 536 covered companies
CURRENT VS SECTOR MEDIAN
+567.36%
vs the sector median at left
BridgeBio Oncology Therapeutics Inc.
Market Cap
$289.27M
Debt to Assets Ratio
0.67%
TTM Avg
0.88%
3Y Avg
0.62%
5Y Avg
N/A
Market Cap
$290.11M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$290.87M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$282.07M
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.92M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$280.84M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$277.81M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$310.39M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $289.27M | 0.67% | 0.88% | 0.62% | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $290.11M | 0.11% | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $290.87M | 0.03% | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $282.07M | 0.29% | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | 0.02% | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $280.84M | 0.00% | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $277.81M | 0.04% | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $274.28M | 0.03% | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $310.39M | 0.00% | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.71M | 0.00% | N/A | N/A | N/A |
Debt/Assets
0.7%
Debt/Equity
0.01
Current Ratio
4.69
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.67% |
| 2026-03-31 | 0.63% |
| 2025-12-31 | 0.62% |
| 2025-09-30 | 0.60% |
| 2025-06-30 | 1.87% |
| 2025-03-31 | 1.77% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 21.06% |
| 2023-09-30 | 30.02% |
